Atherogenic lipid profiles and its management in patients with rheumatoid arthritis

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 845-852

  Nurmohamed, Michael T ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Cholesterol; Dyslipidemia; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRHEUMATIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FIBRIC ACID DERIVATIVE; GOLD; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE PHASE RESPONSE; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; JOINT DESTRUCTION; LIPID METABOLISM; LOW DRUG DOSE; MONOTHERAPY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; LIPIDS; PARTICLE SIZE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149120677     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis. 2002. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum, 46:329-46.
2. Ansell BJ, Navab M, Watson KE, et al. 2004. Anti-inflammatory properties of HDL. Rev Endocr Metab Disord, 5:351-8.
3. Asanuma Y, Kawai S, Aoshima H, et al. 1999. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum, 42:443-7.
4. Banks M, Flint J, Bacon PA, et al. 2000. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease [abstract]. Arthritis Rheum, 43 (Suppl) 9:S385.
5. Boers M, Verhoeven AC, Markusse HM, et al. 1997. Randomised. comparison of combined step-down prednisolon, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet, 350:309-18.
6. Boers M. 2001. Rheumatoid arthritis: Treatment of early disease. Rheum Dis Clin North Am, 27:405-14.
7. Boers M, Nurmohamed MT, Doelman CJ, et al. 2003. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis, 62:842-5.
8. Boers M, Dijkmans B, Gabriel S, et al. 2004. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum, 50:1734-9.
9. Cantin B, Gagnon F, Mooijani S, et al. 1998. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol, 31:519-25.
10. Cauza E, Cauza K, Hanusch-Enserer U, et al. 2002. Intravenous anti-TNF-alpha therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr, 30:1004-7.
11. Dahlqvist SR, Engstrand S, Berglin E, et al. 2006. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol, 35:107-11.
12. Dessein PH, Joffe III, Veller MG, et al. 2005. Traditional arid nontraditional cardiovascular risk factors are associated with atherosclerosis in RA. J Rheumatol, 32:435-42.
13. Fries JF. 2000. Current treatment paradigms in rheumatoid arthritis. Rheumatology, 39 (Suppl) 1:30-5.
14. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. 2006. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther, 8:R82. Epub 2006 Apr 28.
15. Goodson NJ, Solomon DH. 2006. The cardiovascular manifestations of rheumatic diseases. Curr Opin Rheumatol, 18:135-40.
16. Gordon DJ, Knoke J, Probstfield JL, et al. 1986. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation, 74:1217-25.
17. Heldenberg D, Caspi D, Levtov O, et al, 1983. Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis. Clin Rheumatol, 2:387-91.
18. Hurt-Camejo E, Paredes S, Masana L, et al. 2001. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum, 44:2761-7.
19. Jacobsson LT, Turesson C, Gillfe A, et al. 2005. Low incidence of first cardiovascular event in rheumatoid arthritis patients treated with TNF-blockers. J Rheumatol, 32:1213-18.
20. Jacobsson LT, Turesson C, Nilsson JA, et al. 2006. Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis, Dec 11; [Epub ahead of print].
21. Kavanaugh A. 1994. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis, 53:551-2.
22. Kiortsis DN, Mavridis AK, Filippatos TD, et al. 2006. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol, 33:921-3.
23. Kirwan JR. 2001. Systemic low-dose glucocorticoid in rheumatoid arthritis. Rheum Dis Clin North Am, 27:389-403.
24. Kotler DP, 2000. Cachexia. Ann Intern Med, 133:622-34.
25. Lakatos J, Harsagyi A. 1988. Serum total, HDL, LDL cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem, 21:93-6.
26. Lee YH, Choi SJ, Ji JD, et al, 2000. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol, 19:324-25.
27. Lems WF, Dijkmans BAC. 2000. Rheumatoid arthritis: clinical aspects and its variants. In Firestein GS, Panayi GS, Wollheim FA, eds. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. New York: Oxford University Press.p 213-25.
28. Lorber M, Aviram M, Linn S, et al. 1985. Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol, 24:250-5.
29. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. 2005. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum, 52:402-11.
30. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. 2005. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum, 52:722-32.
31. McCarey DW, McInnes IB, Madhok R, et al. 2004. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet, 363:2015-21.
32. McMahon M, Grossman J, FitzGerald J, et al. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 54:2541-9.
33. Menotti A, Lanti M. 2003. Coronary risk factors predicting early and late coronary deaths. Heart, 89:19-24.
34. Menotti A, Kromhout D, Blackburn H, et al. 2004. Forty-year mortality from cardiovascular diseases and all causes of death in the US Railroad cohort of the Seven Countries Study. Eur J Epidemiol, 19:417-24.
35. Munro R, Morrison E, McDonald AG, et al. 1997. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis, 56:374-7.
36. Navab M, Hama SY, Hough GP, et al. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res, 42:1308-17.
37. Park YB, Lee SK, Lee WK. et al. 1999. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol, 26:1701-4.
38. Park YB, Choi HK, Kim MY, et al. 2002. Effects of antirheumatic therapy on serum levels in patients with rheumatoid arthritis: a prospective study. Am J Med, 113:188-93.
39. Peters MJ, Vis M, van Halm VP, et al. 2007. Changes in lipid profile during infliximab treatment and corticosteroid therapy in rheumatoid arthritis. Ann Rheum Dis, Feb 21; Epub ahead of print.
40. Pincus T, Callahan L. 1986. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity, J Rheumatol, 13:841-5.
41. Popa C, Netea MG, Radstake T, et al. 2005. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis, 64:303-5.
42. Rader DJ, Hoeg JM, Brewer HB, Jr. 1994. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med, 120:1012-25.
43. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. 1999. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis, 50:366-8.
44. Rau R. 2000. Methotrexate. In: Firestein GS, Panayi GS, Wollheim FA, eds. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Oxford (NY): Oxford University Press.p 337-50.
45. Redelmeier DA, Tan SH, Booth GL. 1998. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med, 338:1516-20.
46. Rubins HB, Robins SJ, Collins D, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 341:410-18.
47. Sattar N, McCarey DW, Cappel H, et al. 2003. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation, 108:2957-63.
48. Seriolo B, Paolino S, Sulli A, et al. 2006. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci, 1069:414-19.
49. Sharrett AR, Ballantyne CK Coady SA, et al. 2001. Coronary heart disease prediction from lipoprotem cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfiuctions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 104:1109-13.
50. Solomon DH, Karlson EW, Rimm EB, et al. 2003. Cardiovascular morbidity and mortality in women diagnosed witch rheumatoid arthritis. Circulation, 107:1303-7.
51. Spanakis E, Sidiropoulos P, Papadakis J, et al. 2006. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol, 33:2440-6.
52. Sprecher DL, Watkins TR, Behar S, et al. 2003. Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. Am J Cardiol, 91;575-80.
53. Stampfer MJ, Sacks FM, Salvini S, et al. 1991. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med, 325:373-81.
54. Svenson KLG, Lithell H, Hällgren, et al. 1987a. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I Relativity to inflammatory activity. Arch Intern Med, 147:1912-16.
55. Svenson KLG, Lithell H, Hällgren, et al. 1987b. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med, 147:1917-20.
56. The Framingham Study: Coronary risk handbook using HDL-cholesterol for persons over 50. 1978. Bethesda, National Heart, Lung and Blood Institute.
57. Van Doorman S, McGoll G, Wicks IP. 2002. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum, 46:862-73.
58. Van Halm VP, Nielen MM, Nurmohamed MT, et al. 2006. Lipids and inflammation - serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis, Jun 7; [Epub ahead of print].
59. Van Halm VP, Nurmohamed MT, Twisk JW, et al. 2006. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther, Sep 20; 8:R151 [Epub ahead of print].
60. Vis M, Nurmohamed MT, Wolbink G, et al. 2005. Short term effects of infliximab on the lipid Profile in patients with rheumatoid arthritis. J Rheumatol, 32:252-5.
61. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. 1997. Cardiovascularmorbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol, 24:445-51.
62. Walldius G, Jungner I, Holme I, et al. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet, 358:2026-33.
63. Walldius G, Jungner I. 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med, 259:493-519.
64. Walsmith J, Abad L, Kehayias J, Roubenoff R. 2004. Tumor necrosis factor-α production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol, 31:23-9.
65. White D, Fayez S, Doube A. 2006. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med, 119:U2125.